Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient-Reference-Cited by-同舟云学术

Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient

Published:2020-03 Issue:3 Volume:38 Page:377-386
ISSN:0263-6352
Container-title:Journal of Hypertension
language:en
Short-container-title:

Author:

Kotsis Vasilios,Jordan Jens,Stabouli Stella,Antza Christina,Micic Dragan,Jelaković Bojan,Schlaich Markus P.,Nilsson Peter M.,Kreutz Reinhold,Mancia Giuseppe,Tsioufis Kostas,Grassi Guido

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Reference101 articles.

1. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: Part A: Mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment;Kotsis;J Hypertens,2018

2. Redefining type 2 diabetes: ‘diabesity’ or ‘obesity dependent diabetes mellitus’?;Astrup;Obes Rev,2000

3. Syndemics: a new path for global health research;Mendenhall;Lancet,2017

4. Mortality and cardiovascular disease in type 1 and type 2 diabetes;Rawshani;N Engl J Med,2017

5. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial;Riddle;Circulation,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renal tubule-specific Atgl deletion links kidney lipid metabolism to glucagon-like peptide 1 and insulin secretion independent of renal inflammation or lipotoxicity;Molecular Metabolism;2024-03

2. A Review of the Novel Antidiabetic Medications: Efficacy, Safety and Innovation;New Emirates Medical Journal;2023-03

3. Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis;PLOS ONE;2022-09-12

4. Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid;International Journal of Molecular Sciences;2022-04-09

5. New therapies for diabetes mellitus;Pathy's Principles and Practice of Geriatric Medicine;2022-02-18